Adrian Newman-Tancredi PhD DSc
is co-founder and
Chief Scientific Officer
of
Neurolixis Inc.

 

News

Adrian Newman-Tancredi is co-PI of a research grant that has been awarded by International Rett Syndrome Foundation to Neurolixis Inc. Adrian is acting in his capacity as...Read More
Although dementia has high prevalence among the elderly, few drugs are available to treat the Behavioral and Psychological Symptoms of Dementia (BPSD) that often accompany it. Indeed,...Read More
Adrian Newman-Tancredi is PI of a supplementary research grant that has been awarded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Neurolixis Inc. Adrian is...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.

 
  •  

     

     

    NeuroAct Communication

    offers professional and independent advice

    at each stage of early CNS drug discovery. 

     

    Consulting Services

    Contact

  •  

    Newsletter

    Read the latest news from NeuroAct Communication

     


     

    April 2014

    November 2013

  •  

     

     

    NeuroAct Communication  

    was founded by Adrian Newman-Tancredi PhD DSc

    an experienced industrial neuropharmacologist.

     

    Executive Profile

    Endorsements

  •  

      

    Expertise in CNS Drug Discovery

    Preclinical CNS pharmacology of antipsychotics,
    antidepressants, anti-Parkinsonian drugs and analgesics.   

     

    Read more

     

    ClozapineF-15599Milnacipran

  •  

     

    Watch WEBCASTS OF Adrian's lectureS

    Watch Adrian Newman-Tancredi PhD DSc
    lectures on YouTube:

     

    Serotonin "biased agonists" 

    Pharmacology of antipsychotics